A practical reference on reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
=== Mechanism of action === Like other dihydropyridine class calcium channel blockers, lercanidipine blocks L-type calcium channels in the smooth muscle cells of blood vessels, relaxing them and thus lowering blood pressure. In contrast to the non-dihydropyridine calcium channel blockers verapamil and diltiazem, it does not significantly act on calcium channels in the atrioventricular node, and therefore does not decrease heart rate, in usual therapeutic doses.
The 1st Special Forces Group is responsible for operations in the Pacific. Currently, the First Battalion is stationed at Okinawa while the 2nd, 3rd, 4th, and Group Support Battalions are stationed at Joint Base Lewis-McChord, Washington. 1st Special Forces Group's history began at Fort Bragg, NC, in 1955. Four Special Forces Operational Detachments - the 12th, 13th, 14th, and 16th - were selected from the 77th Special Forces Group and transferred to the Pacific theater over the next year. 1st Special Forces Group was officially activated at Fort Buckner, Okinawa, on 24 June 1957, with LTC A. Scott Madding as commander and MSG Robert L. Voss as the sergeant major. The 1st Special Forces Group holds the distinction of having the first and last Special Forces soldiers killed in Vietnam: Captain Harry Cramer killed 21 October 1957, and Captain Richard M. Rees killed 15 December 1973. Decades later, another 1st Special Forces Group soldier became the first American to die by hostile fire in Afghanistan: Sergeant First Class Nathan Chapman killed 2 January 2002. The 1st Special Forces Group on Okinawa was one of two Special Action Forces/Security Assistance Forces (SAF) built around Special Forces Groups. The other was built around the 8th Special Forces Group in Panama. SAF Asia was flexible and 1st Group could task organize a detachment for any time of mission in the Pacific rim. During the Vietnam War, it sent teams to Vietnam for six-month temporary duty.
== Biography == Cantley grew up in West Virginia, remaining there at Wesleyan College where he graduated summa cum laude in chemistry in 1971. Cantley obtained his PhD at Cornell University in Ithaca, New York, where he worked with Gordon Hammes on enzyme kinetics, using FRET to study enzyme conformational changes. In 1975 he moved to Harvard University for a postdoctoral fellowship under Guido Guidotti, where he discovered that an impurity in commercial preparations of ATP, vanadate, acts as a transition state analog for phosphate hydrolysis. In 1978 Cantley became assistant professor of Biochemistry and Molecular Biology at Harvard, being promoted to associate professor in 1981. In 1985, he became a full professor in physiology at Tufts University School of Medicine. In 1985 Cantley and colleagues Malcolm Whitman, David Kaplan, Tom Roberts, and Brian Schaffhausen made the seminal discovery of the existence of phosphoinositide-3-kinase (PI3K). In 1992, Cantley moved to Harvard Medical School as a Professor of Cell Biology and the Director of the Division of Signal Transduction at the former Beth Israel Hospital (now Beth Israel Deaconess Medical Center). In 2003, Cantley became a founding member of the newly formed Department of Systems Biology at Harvard Medical School. In 2007, Cantley also became the Director of Cancer Research at the Beth Israel Deaconess Medical Center. He joined the faculty of Weill Cornell Medicine and NewYork–Presbyterian Hospital in 2012. Dr. Cantley was elected the Chairman of the Board of the Hope Funds for Cancer Research in 2016.
== Discovery == GnIH was discovered in 2000. It is an RFamide peptide that significantly reduced luteinizing hormone release in Coturnix Japonica (Japanese quail). This peptide emerged as the first tropic hormone known to inhibit gonadotropin secretion in the hypothalamic-pituitary-gonadal axis of vertebrates. Subsequent research identified GnIH peptide homologs in variety of mammals, including humans.
==== Elderly ==== According to the package insert, clinical studies did not show differences in efficacy and safety of ceftriaxone in geriatrics compared to younger patients but "greater sensitivity of some older individuals cannot be ruled out."
Sources: en.wikipedia.org
== External links == "Amylase, Alpha", I.U.B.: 3.2.1.11,4-α-D-Glucan glucanohydrolase. "Amylase, Alpha", I.U.B.: 3.2.1.11,4-α-D-Glucan glucanohydrolase. Beta-amylase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Centralized market escrow allows a market to close down and "exit" with the buyer's and vendor's cryptocurrency at any time. This has happened on several occasions such as with BlackBank, Evolution, and Wall Street Market. Individual vendors often reach a point of reputation maturity whereby they have sold sufficient product reliably to have gained a significant reputation and accumulated escrowed funds; many may choose to exit with the funds rather than compete at the higher-volume higher-priced matured product level.
{\displaystyle {{\frac {q}{A}}_{min}}=C{{h}_{fg}}{{\rho }_{v}}{{\left[{\frac {\sigma g\left({{\rho }_{L}}-{{\rho }_{v}}\right)}{{\left({{\rho }_{L}}+{{\rho }_{v}}\right)}^{2}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
== Side effects == Side effects of doxylamine include dizziness, drowsiness, and dry mouth, among others. Doxylamine is a potent anticholinergic and has a side-effect profile common to such drugs, including blurred vision, dry mouth, constipation, muscle incoordination, urinary retention, mental confusion, and delirium. Because of its relatively long elimination half-life (10–12 hours), doxylamine is associated with next-day effects including sedation, drowsiness, grogginess, dry mouth, and tiredness when used as a hypnotic. This next-day sedation may be described as a "hangover effect". The shorter elimination half-life of diphenhydramine (4–8 hours) compared to doxylamine may give it an advantage over doxylamine as a sleep aid in this regard. Antihistamines like doxylamine are sedating initially but tolerance occurs with repeated use and can result in rebound insomnia upon discontinuation. Occasional case reports of coma and rhabdomyolysis have been reported with doxylamine overdose. This pattern is in contrast to diphenhydramine. Studies of doxylamine's carcinogenicity in mice and rats have produced positive results for both liver and thyroid cancer, especially in the mouse. The carcinogenicity of the drug in humans is not well-studied, and the International Agency for Research on Cancer lists the drug as "not classifiable as to its carcinogenicity to humans". Continuous and/or cumulative use of anticholinergic medications, including first-generation antihistamines, is associated with a higher risk of cognitive decline and dementia in older people.
Sources: en.wikipedia.org
The use of fluorescence detection techniques can be expanded into applications beyond data collection; a widely used method of cell and droplet sorting in microfluidics is fluorescence-activated sorting, where droplets are sorted into different channels or collection outlets based on their fluorescence intensity. Fluorescent quantum dots have been used to develop biosensing platforms and drug delivery in microfluidic devices. Quantum dots are useful due to their small size, precise excitation wavelength, and high quantum yield. These are advantages over traditional dyes which may interfere with the activity of the studied compound. However, the bulk creation and conjugation of quantum dots to molecules of interest remains a challenge. Microfluidic devices that conjugate nucleotides with quantum dots have been designed to solve this issue by significantly reducing the conjugation time from two days to minutes. DNA-quantum dot conjugates are of importance to detect complementary DNA and miRNA in biological systems.
== Regulation == Central to the physiologic maintenance of GFR is the differential vasoconstriction of the afferent (input) and efferent (output) arterioles. Vasodilation of the afferent or vasoconstriction of the efferent arteriole increases GFR. Conversely, vasoconstriction of the afferent or vasodilation of the efferent will decrease GFR. There are multiple mechanisms that the body has to regulate the constriction or dilation of these arterioles: local feedback within the kidney, hormonal regulation, and sympathetic nervous control. These systems are closely intertwined. The kidney can maintain a relatively constant GFR even as mean arterial pressure changes. Local feedback within the kidney (renal autoregulation) includes the myogenic response and tuberoglomerular feedback. In the myogenic response, increased stretch of the afferent arteriole due to higher blood pressure results in afferent vasoconstriction, thereby preventing an increase in GFR. With tuberoglomerular feedback, the macula densa cells at the downstream nephron tubule senses changes in ion levels. If sodium chloride sodium levels in the urinary filtrate are too high, the macula densa signals to constrict the afferent arteriole; if too low, the signal is to vasodilate the afferent arteriole and to release renin (activating the RAAS system). The RAAS system is the major hormonal control of GFR. Low blood pressure activates the RAAS system, increasing the amount of the hormone angiotensin II. Angiotensin II binds to receptors on the efferent arteriole; the resulting efferent vasoconstriction increases GFR.
Oskar Stross, Austrian Consul General Mervyn Whitfield, Political Branch, Public Security, Alexandria, 1917 General Sir Reginald Wingate, 1915 Judge Youssef Zulficar Pasha (Grand Cordon) Oswald Longstaff Prowde, English civil engineer Lt Colonel William John Ainsworth, CBE DSO Durham Light Infantry (3rd Class 1919),
== Chemistry == Several chemical factors affect the ionophore activity. The activity of an ionophore-metal complex depends on its geometric configuration and the coordinating sites and atoms which create coordination environment surrounding the metal center. This affects the selectivity and affinity towards a certain ion. Ionophores can be selective to a particular ion but may not be exclusive to it. Ionophores facilitate the transport of ions across biological membranes most commonly via passive transport, which is affected by lipophilicity of the ionophore molecule. The increase in lipophilicity of the ionophore-metal complex enhances its permeability through lipophilic membranes. The hydrophobicity and hydrophilicity of the complex also determines whether it will slow down or ease the transport of metal ions into cell compartments. The reduction potential of a metal complex influences its thermodynamic stability and affects its reactivity. The ability of an ionophore to transfer ions is also affected by the temperature.
=== Softmaxxing === "Softmaxxing" is a subset of looksmaxxing that refers to non-invasive and simple practices used to achieve minor improvements to one's appearance. These include skincare, grooming, clothing choices, and general fitness such as weight management and exercise. Additional less conventional practices are also included in the scope of softmaxxing; popular examples include "mewing", which involves suctioning one's tongue to the roof of the mouth with the intention of an improved jaw and facial structure, and "NoFap", where one abstains from masturbation for perceived physical and mental benefits. Such practices come up more often in looksmaxxing discourse due to their niche nature. Practices associated with softmaxxing were previously popularized among men by magazines such as GQ, Esquire, and Men's Health, which share skincare and hairstyle advice.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.